AAPL 143.43 +0.48999 0.34279436FB 357.48 +1.78 0.50042135GOOG 2792.93 +12.5898 0.45281667MSFT 294.8 +0.5 0.16989467NVDA 212.46 +1.33 0.6299445WBA 48.02 -0.380001 -0.78512615ZNGA 7.66 -0.0799999 -1.0335908
AAPL 143.43 +0.48999 0.34279436FB 357.48 +1.78 0.50042135GOOG 2792.93 +12.5898 0.45281667MSFT 294.8 +0.5 0.16989467NVDA 212.46 +1.33 0.6299445WBA 48.02 -0.380001 -0.78512615ZNGA 7.66 -0.0799999 -1.0335908

Financial Summary VRPX Quote Virpax Phar

Virpax Pharmaceuticals, Inc. Quote

Virpax Pharmace (VRPX)

5.26 0.0400004 Healthcare
Stock Performance rating :
Recommendation :
Not Available
Symbol VRPX
Price 5.26
Beta 0.00
Vol Avg 6.34 M
Mkt cap 28.98 M
Shares Not Available
Last Div Not Available
Div Yield Not Available
DCF Unlevered Not Available Not Available
DCF Levered Not Available Not Available
ROE Not Available Not Available
ROA Not Available Not Available
Operating Margin Not Available Not Available
Debt/Equity Not Available Not Available
P/E Not Available Not Available
P/B Not Available Not Available
All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 0 0 0 0 0
COGS 0 0 0 0 0
GrossProfit 0 0 0 0 0
Depreciation (included in COGS) 0 0 0 0 0
StockBasedCompe (included in COGS) 0 0 0 0 0
ResearchAndDeve 0 0 0 0 0
SalesGeneralAnd 0 0 0 0 0
OperatingIncome 0 0 0 0 0
InterestExpense 0 0 0 0 0
OtherIncome 0 0 0 0 0
IncomeBeforeTax 0 0 0 0 0
ProvisionForInc 0 0 0 0 0
NetIncome 0 0 0 0 0
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 0 0 0 0 0
ShortTermInvest 0 0 0 0 0
Cash 0 0 0 0 0
AccountReceivab 0 0 0 0 0
Inventories 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
OtherCurrentAss 0 0 0 0 0
TotalCurrentAss 0 0 0 0 0
PPE 0 0 0 0 0
AccumulatedDepr 0 0 0 0 0
NetPPE 0 0 0 0 0
EquityAndOtherI 0 0 0 0 0
Goodwill 0 0 0 0 0
IntangibleAsset 0 0 0 0 0
OtherLTAssets 0 0 0 0 0
TotalNonCurrent 0 0 0 0 0
TotalAssets 0 0 0 0 0
ShortTermDebt 0 0 0 0 0
AccountsPayable 0 0 0 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 0 0 0 0 0
DeferredRevenue 0 0 0 0 0
OtherCurrentLia 0 0 0 0 0
TotalCurrentLia 0 0 0 0 0
Debt 0 0 0 0 0
DeferredTaxesLi 0 0 0 0 0
DeferredRevenue 0 0 0 0 0
OtherLTLiabilit 0 0 0 0 0
TotalNonCurrent 0 0 0 0 0
TotalLiabilitie 0 0 0 0 0
CommonStock 0 0 0 0 0
AdditionalPaidI 0 0 0 0 0
RetainedEarning 0 0 0 0 0
AccumulatedOthe 0 0 0 0 0
TotalStockholde 0 0 0 0 0
TotalLiabilitie 0 0 0 0 0
Cash Flow Statement
Year 20142015201620172018
NetIncome 0 0 0 0 0
Depreciation 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
StockBasedCompe 0 0 0 0 0
AccountsReceiva 0 0 0 0 0
InventoryCS 0 0 0 0 0
AccountsPayable 0 0 0 0 0
OtherWorkingCap 0 0 0 0 0
OtherNonCashIte 0 0 0 0 0
NetCashProvided 0 0 0 0 0
InvestmentsInPP 0 0 0 0 0
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve 0 0 0 0 0
SalesMaturities 0 0 0 0 0
PurchasesOfInta 0 0 0 0 0
OtherInvestingA 0 0 0 0 0
NetCashUsedForI 0 0 0 0 0
DebtIssued 0 0 0 0 0
DebtRepayment 0 0 0 0 0
CommonStockIssu 0 0 0 0 0
CommonStockRepu 0 0 0 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 0 0 0 0 0
NetCashProvided 0 0 0 0 0
NetChangeInCash 0 0 0 0 0
CashAtBeginning 0 0 0 0 0
CashAtEndOfPeri 0 0 0 0 0
Retained Earnings
Year 20142015201620172018
RetainedEarning -----
NetIncome -----
StockDividend -----
DividendPaid -----
RetainedEarning -----
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE -----
DeprAnnual 0----
CapitalExpendit 00000
NetPPE -----
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0----
Amortization 0----
NewPurchases 0----
intAndGW -----
Company Profile

CEO

Mr. Anthony P. Mack

Sector

Healthcare

Industry

Biotechnology

Exchange

Nasdaq Global Select

Description

Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.